Novo on Tuesday said its next-generation obesity drug, CagriSema, showed 25% weight loss on average among adult women in a new analysis conducted after a late-stage trial.Â
The Danish company said further work is needed to confirm the hypotheses of two post-study analyses. Still, the results are the latest evidence that the experimental injection can improve upon the weight loss and other benefits offered by Novo’s GLP-1 drug semaglutide, the active ingredient in its blockbuster obesity shot Wegovy and diabetes counterpart Ozempic.
CagriSema, a combination of semaglutide and another drug called cagrilintide that targets the amylin pathway, is expected to launch early next year. Obesity drug leaders Novo and Eli Lilly have built new treatments around amylin, which involves a hormone released in the pancreas alongside insulin that helps regulate hunger and fullness, hoping it will give them a new revenue stream beyond existing GLP-1s….
